Expertise in
2
conditions

Carolien P. Schroder

Amsterdam, NH, NL 
Expertise in
2
conditions
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Carolien Schroder practices in Amsterdam, Netherlands. Schroder is highly rated in 2 conditions, according to our data. Their top areas of expertise are Breast Cancer in Men, Breast Cancer, Cerebral Hypoxia, Ovarian Cancer, and Mastectomy.

Their clinical research consists of co-authoring 69 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Amsterdam, NH, Netherlands
Other Locations
Groningen, GR, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
SONImage Study: Can Molecular Imaging Predict Outcome to First-line Endocrine Treatment ± CDK 4/6 Inhibition in Advanced ER+ Breast Cancer
SONImage Study: Can Molecular Imaging Predict Outcome to First-line Endocrine Treatment ± CDK 4/6 Inhibition in Advanced ER+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drugs: ddAC-CP-Olaparib, ddAC-mini CTC
Study Phase: Phase 3
Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging IMPACT: IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer
Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging IMPACT: IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Early Identification of Patients Who Benefit From Palbociclib in Addition to Letrozole
Early Identification of Patients Who Benefit From Palbociclib in Addition to Letrozole
Enrollment Status: Completed
Publish Date: October 12, 2022
Intervention Type: Drug, Device
Study Drugs: Palbociclib, Letrozole
Study Phase: Phase 2
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
Enrollment Status: Terminated
Publish Date: July 19, 2022
Intervention Type: Drug
Study Drugs: Carboplatin, Atezolizumab
Study Phase: Phase 2
Can 89Zr-atezolizumab PET Scan Identify Patients With Metastatic Invasive Lobular Breast Cancer Who Will Respond to Chemotherapy-immune Checkpoint Inhibition?
Can 89Zr-atezolizumab PET Scan Identify Patients With Metastatic Invasive Lobular Breast Cancer Who Will Respond to Chemotherapy-immune Checkpoint Inhibition?
Enrollment Status: Terminated
Publish Date: July 01, 2022
Intervention Type: Other
Study Phase: Not Applicable
FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide
FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide
Enrollment Status: Completed
Publish Date: November 27, 2019
Intervention Type: Drug, Procedure
Study Phase: Phase 2
View 7 Less Clinical Trials

69 Total Publications

Cyclin E1 overexpression triggers interferon signaling and is associated with antitumor immunity in breast cancer.
Cyclin E1 overexpression triggers interferon signaling and is associated with antitumor immunity in breast cancer.
Journal: Journal for immunotherapy of cancer
Published: March 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Schroder's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile